To discover whether patient experience mirrors HCP perception that a particular Tyrosine Kinase Inhibitor (TKI) leads to more severe side effects than other agents in the same class
Identify side effects and their impact on quality of life
- Understand management of side effects
- Evaluate whether adherence is a problem
- Qualitative analysis of online commentary; applying themes, topics and sentiment
- Collection of relevant data across 3 markets using Klood Radar
- Digital Landscape created around the tools and apps available for CML patients
Understanding Patient Experience
Chronic myeloid leukaemia (CML) treatment
- Patients don’t always use drug names when discussing their experiences
- Low patient commentary volumes as expected due to particular markets and typical age of diagnosis for CML patients
- Concern around the volume of adverse event reporting
- In all three countries, patients discussed the emotional, physical and wider impact the disease has had on their quality of life
- The six key areas of discussion were: satisfaction with treatment, adherence to medication, resistance to drugs, dosage, cost, and questions about fertility
- Common side effects identified were: muscle and joint pain, bleeds (eyes), stomach cramps, night sweats, rashes and nausea.
- Less common side effects but those that caused the most concern included: brain haemorrhage, hair loss, pleural effusion, heart problems, hepatitis B and liver function.
- There was no significant increase in levels of Adverse Event Reporting when compared to traditional market research methodologies
- Patient perception did not mirror that of HCPs in terms of side effects. There was no distinction between any of the TKIs and the agent in question.
What they say…
“MMRI have successfully delivered several projects for us using their digital intelligence methodology, always on budget and always on time. They have used their technology, MMRI Radar to access insights from hard to reach audiences in the healthcare sector, and have also demystified the “social data’ / alternative research approach; we have seen how their experience in the healthcare sector has enabled them to valuably interrogate this alternative data source. This has added a whole new layer to the insights we generate, most significantly capturing “in the moment” patient ” commentary on various stages of their disease journey.”
Research Director, Earthworks